Related Experiment Video
Updated: May 19, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide-Associated ITP
Christina I Herold1, Cristina Gasparetto, Gowthami M Arepally
1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
Related Concept Videos
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Cytotoxic Edema: Pathophysiology
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions